Protein formulations and methods of making same
US-2015361170-A1 · Dec 17, 2015 · US
Treatment of inflammatory bowel disease
US2019240297A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019240297-A1 |
| Application number | US-201716336793-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 29, 2017 |
| Priority date | Sep 30, 2016 |
| Publication date | Aug 8, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses a novel therapeutic axis NTPDase8 enzyme, P2Y6 and/or P2Y2 receptors, and provides methods, enzymes and/or antagonists for remedying inflammatory bowel diseases.
First claim
Opening claim text (preview).
What is claimed is: 1 - 23 . (canceled) 24 . A method for the treatment or prevention of a chronic inflammatory bowel disease in a mammal, the method comprising administering to said mammal an effective amount of a composition comprising a Nucleoside triphosphate diphosphohydrolase (NTPDase) enzyme, wherein the enzyme is selected from the group consisting of: NTPDase3 and NTPDase8. 25 . The method of claim 24 , wherein said NTPDase enzyme is in a concentration sufficient to decrease a concentration of nucleoside triphosphate or diphosphate in a colon lumen of said mammal. 26 . The method of claim 25 , wherein said nucleoside triphosphate or diphosphate is selected from the group consisting of UTP, UDP, ADP and ATP. 27 . The method of claim 25 , wherein said composition further comprises an inhibitor or antagonist of P2Y 6 receptor. 28 . The method of claim 25 , wherein said composition further comprises an inhibitor or antagonist of P2Y 2 receptor. 29 . The method of claim 25 , wherein the administering comprises administering orally, enterally or intrarectally. 30 - 42 . (canceled) 43 . The method according to claim 24 , wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease, ulcerative colitis and GI tract cancer. 44 - 49 . (canceled) 50 . The method according to claim 24 , wherein said enzyme is NTPDase8.
Assignees
Inventors
Classifications
- A61K38/46Primary
Hydrolases (3) · CPC title
Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase · CPC title
G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Determining the risk of developing a disease · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019240297A1 cover?
- The present invention discloses a novel therapeutic axis NTPDase8 enzyme, P2Y6 and/or P2Y2 receptors, and provides methods, enzymes and/or antagonists for remedying inflammatory bowel diseases.
- Who is the assignee on this patent?
- Univ Laval
- What technology area does this patent fall under?
- Primary CPC classification A61K38/46. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Aug 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).